BC Week In Review | Aug 31, 2018
Company News

GeoVax, PharmaJet partner to study needle-free delivery of Zika vaccine

GeoVax Labs Inc. (OTCQB:GOVX) partnered with PharmaJet Inc. (Golden, Colo.) to evaluate PharmaJet’s needle-free injection system to deliver GeoVax’s preclinical Zika vaccine GEO-ZM02. The studies will be conducted at the Division of Vector-Borne Diseases, U.S....
BC Extra | Dec 16, 2016
Financial News

Vaccibody raises NOK220M in private placement

Vaccine company Vaccibody A/S (Oslo, Norway) raised NOK220 million ($26 million) through the sale of 880,000 shares at NOK250 in a private placement with new and existing investors. Vaccibody develops personalized cancer neoantigen vaccines. Its...
BC Week In Review | Sep 5, 2016
Clinical News

VB10: Interim Phase I/IIa data

Interim data from 16 patients in the Phase I portion of the open-label, German Phase I/IIa VB C-01 trial showed that 3 doses of 3 mg intramuscular VB10.16 were well tolerated with no serious adverse...
BC Week In Review | Sep 15, 2014
Clinical News

Afluria regulatory update

CSL's bioCSL Inc. (formerly CSL Biotherapies) subsidiary and PharmaJet Inc. (Golden, Colo.) said FDA approved the PharmaJet Stratis 0.5 mL Needle-Free Jet Injector from PharmaJet for delivery of bioCSL's Afluria seasonal influenza vaccine in individuals...
BC Week In Review | Oct 18, 2010
Company News

Inviragen, PharmaJet, National Institutes of Health infectious, drug delivery news

The companies received a five-year, $15.5 million contract from NIH's National Institute of Allergy and Infectious Diseases (NIAID) to develop a needle-free dengue vaccine. The companies are developing DENVax , Inviragen's tetravalent attenuated live dengue vaccine...
BC Week In Review | Apr 12, 2010
Company News

PharmaJet, Netherlands Vaccine Institute deal

PharmaJet and the institute partnered to evaluate PharmaJet's intra-dermal needle-free delivery technology with the institute's marketed Salk inactivated polio vaccine (IPV). The partners will share expenses and conduct the trials, which would include non-inferiority studies,...
Items per page:
1 - 6 of 6
BC Week In Review | Aug 31, 2018
Company News

GeoVax, PharmaJet partner to study needle-free delivery of Zika vaccine

GeoVax Labs Inc. (OTCQB:GOVX) partnered with PharmaJet Inc. (Golden, Colo.) to evaluate PharmaJet’s needle-free injection system to deliver GeoVax’s preclinical Zika vaccine GEO-ZM02. The studies will be conducted at the Division of Vector-Borne Diseases, U.S....
BC Extra | Dec 16, 2016
Financial News

Vaccibody raises NOK220M in private placement

Vaccine company Vaccibody A/S (Oslo, Norway) raised NOK220 million ($26 million) through the sale of 880,000 shares at NOK250 in a private placement with new and existing investors. Vaccibody develops personalized cancer neoantigen vaccines. Its...
BC Week In Review | Sep 5, 2016
Clinical News

VB10: Interim Phase I/IIa data

Interim data from 16 patients in the Phase I portion of the open-label, German Phase I/IIa VB C-01 trial showed that 3 doses of 3 mg intramuscular VB10.16 were well tolerated with no serious adverse...
BC Week In Review | Sep 15, 2014
Clinical News

Afluria regulatory update

CSL's bioCSL Inc. (formerly CSL Biotherapies) subsidiary and PharmaJet Inc. (Golden, Colo.) said FDA approved the PharmaJet Stratis 0.5 mL Needle-Free Jet Injector from PharmaJet for delivery of bioCSL's Afluria seasonal influenza vaccine in individuals...
BC Week In Review | Oct 18, 2010
Company News

Inviragen, PharmaJet, National Institutes of Health infectious, drug delivery news

The companies received a five-year, $15.5 million contract from NIH's National Institute of Allergy and Infectious Diseases (NIAID) to develop a needle-free dengue vaccine. The companies are developing DENVax , Inviragen's tetravalent attenuated live dengue vaccine...
BC Week In Review | Apr 12, 2010
Company News

PharmaJet, Netherlands Vaccine Institute deal

PharmaJet and the institute partnered to evaluate PharmaJet's intra-dermal needle-free delivery technology with the institute's marketed Salk inactivated polio vaccine (IPV). The partners will share expenses and conduct the trials, which would include non-inferiority studies,...
Items per page:
1 - 6 of 6